There has been a sharp increase in colorectal and pancreatic cancer rates among Americans under 55 years, despite declines in older adults, according to a new study.
Findings from a new study reveal how hurricanes and the pandemic disrupted colorectal cancer (CRC) screenings in Puerto Rico, leading to a rise in late-stage diagnoses.
The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Patient navigation and mailed outreach improved colorectal cancer screening rates in rural clinics, but follow-up colonoscopy participation remains low.